EUVIMEDEUVIMED entdecken
Crossref

Biologics and small molecule inhibitors for hidradenitis suppurativa

Terri Shih, Devea R. De, Vivian Y. Shi, Jennifer L. Hsiao

Dermatological Reviews · 2022

DOI: 10.1002/der2.110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatological Reviews, 2022. Verfasst von Terri Shih und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 116 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hidradenitis suppurativa (HS) is a debilitating, chronic inflammatory dermatosis that is often recalcitrant to first‐line treatments. Though mechanisms underlying its pathology remain unclear, a number of upregulated inflammatory cytokines (including tumor necrosis factor‐α [TNF‐α], interleukin [IL]‐1, IL‐17, IL‐12, and IL‐23) have been identified in HS, leading to a growing investigation of targeted biologic therapies in moderate‐to‐severe HS.

Objective

We aim to review the current literature on biologics and small molecule inhibitors that have been used to treat HS and discuss mechanisms of action, dosing, safety considerations, and recommendations for use.

Findings

Biologics that have been reported to treat HS include TNF‐α inhibitors (adalimumab, infliximab, golimumab, and certolizumab), IL‐1 inhibitors (anakinra and canakinumab), IL‐12/23 inhibitor (ustekinumab), IL‐23 inhibitors (guselkumab, risankizumab, and tildrakizumab), IL‐17 inhibitors (secukinumab, ixekizumab, and brodalumab), and small molecule inhibitors (tofacitinib and sirolimus). Though adalimumab is currently the only FDA‐approved agent to treat HS, those who do not have an optimal response may still benefit from a different anti‐TNF agent, particularly high dose infliximab. A number of other targeted treatments have also shown promising results in small prospective studies for consideration in HS patients. Additional considerations in biologic therapy include mitigating patient concerns about injection reactions and choosing agents that may also treat comorbid conditions.

Conclusion

This review summarizes the current literature on the use of biologics and small molecule inhibitors in HS. There remains a significant and continued need to expand the treatment armamentarium for moderate to severe HS

Zitieren

APA

Shih, T., De, D. R., Shi, V. Y., & Hsiao, J. L. (2022). Biologics and small molecule inhibitors for hidradenitis suppurativa. Dermatological Reviews. https://doi.org/10.1002/der2.110

Vancouver

Shih T, De DR, Shi VY, Hsiao JL. Biologics and small molecule inhibitors for hidradenitis suppurativa. Dermatological Reviews. 2022. doi:10.1002/der2.110

BibTeX
@article{Shih2022,
  author = {Shih, Terri and De, Devea R. and Shi, Vivian Y. and Hsiao, Jennifer L.},
  title = {Biologics and small molecule inhibitors for hidradenitis suppurativa},
  journal = {Dermatological Reviews},
  year = {2022},
  doi = {10.1002/der2.110}
}
Kostenlos starten →